Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456 · see citing works

RNA interference

Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,583 · see citing works

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047 · see citing works

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857 · see citing works

Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade

Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · see citing works

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Benson, M. D., Waddington‐Cruz, M., Berk, J. L., Polydefkis, M. J., Dyck, P. J. B., Wang, A. K., Planté‐Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452 · see citing works

Natural History and Outcome in Systemic AA Amyloidosis

Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,025 · see citing works

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

Palladini, G. O., Dispenzieri, A. A., Gertz, M. A., Kumar, S. K., Wechalekar, A. D., Hawkins, P. N., Schönland, S. O., Hegenbart, U., Comenzo, R. L., Kastritis, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7614 · Cited by 978 · see citing works

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971 · see citing works

Tafamidis for transthyretin familial amyloid polyneuropathy

Coelho, T., Maia, L. F., SILVA, A. C. F. D., Waddington‐Cruz, M., Planté‐Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 812 · see citing works

Guideline of transthyretin-related hereditary amyloidosis for clinicians

Ando, Y., Coelho, T., Berk, J. L., Waddington‐Cruz, M., Ericzon, B., Ikeda, S.-I., Lewis, W. D., Obici, L. P., Planté‐Bordeneuve, V., Rapezzi, C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-31 · Cited by 720 · see citing works

Transthyretin (TTR) Cardiac Amyloidosis

Ruberg, F. L., & Berk, J. L. (2012) · Circulation · doi:10.1161/circulationaha.111.078915 · Cited by 710 · see citing works

Repurposing Diflunisal for Familial Amyloid Polyneuropathy

Berk, J. L., Suhr, O. B., Obici, L. P., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 709 · see citing works

Association Between Nonsteroidal Anti-inflammatory Drugs and Upper Gastrointestinal Tract Bleeding/Perforation

Hernández–Dı́az, S., & Rodríguez, L. A. G. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2093 · Cited by 701 · see citing works

Fibril in senile systemic amyloidosis is derived from normal transthyretin.

Westermark, P., Sletten, K., Johansson, B., & Cornwell, G. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2843 · Cited by 698 · see citing works

Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines

Sipe, J. D., Benson, M. D., Buxbaum, J. N., Ikeda, S.-I., Merlini, G., Saraiva, M. J., & Westermark, P. (2016) · Amyloid · doi:10.1080/13506129.2016.1257986 · Cited by 603 · see citing works

Lipid nanoparticles enabling gene therapies: from concepts to clinical utility

Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592 · see citing works

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein

Gillmore, J. D., Lovat, L. B., Persey, M. R., Pepys, M. B., & Hawkins, P. N. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05252-1 · Cited by 586 · see citing works

Genotype and Phenotype of Transthyretin Cardiac Amyloidosis

Maurer, M. S., Hanna, M. A., Grogan, M. A., Dispenzieri, A. A., Witteles, R. M., Drachman, B. M., Judge, D. P., Lenihan, D. J., Gottlieb, S. S., Shah, S. J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.596 · Cited by 536 · see citing works

Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin).

Saraiva, M. J., Birken, S., Costa, P., & Goodman, D. S. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111390 · Cited by 433 · see citing works

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

Lachmann, H. J., Gallimore, J. R., Gillmore, J. D., Carr-Smith, H. D., Bradwell, A. R., Pepys, M. B., & Hawkins, P. N. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04433.x · Cited by 431 · see citing works

Transthyretin-Related Familial Amyloidotic Polyneuropathy

Ando, Y., Nakamura, M., & Araki, S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1057 · Cited by 416 · see citing works

Amyloid and Amyloidosis

Glynn, L. E. (1981) · Immunology · Cited by 412 · see citing works

Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein

Monaco, H. L., Rizzi, M., & Coda, A. (1995) · Science · doi:10.1126/science.7754382 · Cited by 410 · see citing works

Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP‐met30)

Holmgren, G., Steen, L., Ekstedt, J., Groth, C., Ericzon, B. ‐., Eriksson, S., Andersen, O., Karlberg, I. H., Nordén, G., Nakazato, M., et al. (1991) · Clinical Genetics · doi:10.1111/j.1399-0004.1991.tb03085.x · Cited by 395 · see citing works

Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis

Quarta, C. C., Solomon, S. D., Uraizee, I., Kruger, J., Longhi, S., Ferlito, M., Gagliardi, C., Milandri, A., Rapezzi, C., & Falk, R. H. (2014) · Circulation · doi:10.1161/circulationaha.113.006242 · Cited by 345 · see citing works

THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis

Coelho, T., Maurer, M. S., & Suhr, O. B. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.754348 · Cited by 343 · see citing works

Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective

Rapezzi, C., Quarta, C. C., Obici, L. P., Perfetto, F., Longhi, S., Salvi, F., Biagini, E., Lorenzini, M., Grigioni, F., Leone, O., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs123 · Cited by 330 · see citing works

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321 · see citing works

Liver Transplantation for Hereditary Transthyretin Amyloidosis

Ericzon, B., Wilczek, H., Larsson, M., Wijayatunga, P. D. C., Stangou, A. J., Peña, J., Furtado, E., Barroso, E., Daniel, J., Samuel, D., et al. (2015) · Transplantation · doi:10.1097/tp.0000000000000574 · Cited by 311 · see citing works

Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations

Rowczenio, D. M., Noor, I., Gillmore, J. D., Lachmann, H. J., Whelan, C. J., Hawkins, P. N., Obici, L. P., Westermark, P., Grateau, G., & Wechalekar, A. D. (2014) · Human Mutation · doi:10.1002/humu.22619 · Cited by 307 · see citing works

“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy

Conceição, I. M., González‐Duarte, A., Obici, L. P., Schmidt, H., Simoneau, D., Ong, M., & Amass, L. (2015) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12153 · Cited by 298 · see citing works

Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry

Herlenius, G., Wilczek, H., Larsson, M., & Ericzon, B. (2004) · Transplantation · doi:10.1097/01.tp.0000092307.98347.cb · Cited by 274 · see citing works

Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.

Huang, S. K., Mayhew, E. G., Gilani, S., Lasiç, D. D., Martin, F. J., & Papahadjopoulos, D. (1992) · PubMed · Cited by 274 · see citing works

Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis

Sekijima, Y., Dendle, M. A., & Kelly, J. W. (2006) · Amyloid · doi:10.1080/13506120600960882 · Cited by 269 · see citing works

Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)

Ruberg, F. L., Maurer, M. S., Judge, D. P., Zeldenrust, S. R., Skinner, M. M., Kim, A. Y., Falk, R. H., Cheung, K. N., Patel, A. R., Pano, A., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.04.015 · Cited by 263 · see citing works

Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat.

Soprano, D. R., Herbert, J., Soprano, K. J., Schon, E. A., & Goodman, D. S. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39100-7 · Cited by 254 · see citing works

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

Castaño, A., Drachman, B. M., Judge, D. P., & Maurer, M. S. (2014) · Heart Failure Reviews · doi:10.1007/s10741-014-9462-7 · Cited by 254 · see citing works

The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation

Adams, D. (2000) · Brain · doi:10.1093/brain/123.7.1495 · Cited by 253 · see citing works

Evolving landscape in the management of transthyretin amyloidosis

Hawkins, P. N., Ando, Y., Dispenzeri, A., González‐Duarte, A., Adams, D., & Suhr, O. B. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1068949 · Cited by 243 · see citing works

Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)

Planté‐Bordeneuve, V., Ferreira, A. C., Lalu, T., Zaros, C., Lacroix, C., Adams, D., & Saïd, G. (2007) · Neurology · doi:10.1212/01.wnl.0000267338.45673.f4 · Cited by 243 · see citing works

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

Adams, D., Suhr, O. B., Hund, E., Obici, L. P., Tournev, I., Campistol, J. M., Slama, M., Hazenberg, B. P. C., & Coelho, T. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000289 · Cited by 241 · see citing works

Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)‐type I in Póvoa do Varzim and Vila do Conde (north of Portugal)

Sousa, A., Coelho, T., Barros, J., & Sequeiros, J. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320600606 · Cited by 236 · see citing works

Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe

Parman, Y., Adams, D., Obici, L. P., Galán, L., Guergueltcheva, V., Suhr, O. B., & Coelho, T. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000288 · Cited by 234 · see citing works

Cardiac amyloidosis: Updates in diagnosis and management

Mohty, D., Damy, T., Cosnay, P., Echahidi, N., Casset-Senon, D., Virot, P., & Jaccard, A. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.06.051 · Cited by 228 · see citing works

Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas

Koike, H., Tanaka, F., Hashimoto, R., Tomita, M., Kawagashira, Y., Iijima, M., Fujitake, J., Kawanami, T., Kato, T., Yamamoto, M., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301299 · Cited by 210 · see citing works

Transthyretin mutations in hyperthyroxinemia and amyloid diseases

Saraiva, M. J. (2001) · Human Mutation · doi:10.1002/humu.1132 · Cited by 206 · see citing works

Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases

Kelly, J. W. (1997) · Structure · doi:10.1016/s0969-2126(97)00215-3 · Cited by 205 · see citing works

Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant

Sattianayagam, P. T., Hahn, A. F., Whelan, C. J., Gibbs, S. D., Pinney, J. H., Stangou, A. J., Rowczenio, D. M., Pflugfelder, P. W., Fox, Z. V., Lachmann, H. J., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr383 · Cited by 195 · see citing works

Transthyretin: A multifaceted protein

Vieira, M., & Saraiva, M. J. (2014) · BioMolecular Concepts · doi:10.1515/bmc-2013-0038 · Cited by 185 · see citing works

Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

Cardoso, I., Martins, D. F., Ribeiro, T., Merlini, G., & Saraiva, M. J. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-74 · Cited by 184 · see citing works

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

Adams, D., Suhr, O. B., Dyck, P. J. B., Litchy, W. J., Leahy, R. G., Chen, J., Gollob, J., & Coelho, T. (2017) · BMC Neurology · doi:10.1186/s12883-017-0948-5 · Cited by 176 · see citing works

Progression of transthyretin amyloid neuropathy after liver transplantation

Liepnieks, J. J., Zhang, L. Q., & Benson, M. D. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ea15d4 · Cited by 158 · see citing works

Diflunisal for ATTR Cardiac Amyloidosis

Castaño, A., Helmke, S. T., Alvarez, J., Delisle, S., & Maurer, M. S. (2012) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2012.00303.x · Cited by 156 · see citing works

Rapid progression of familial amyloidotic polyneuropathy

Adams, D., Coelho, T., Obici, L. P., Merlini, G., Mincheva, Z., Suanprasert, N., Bettencourt, B. R., Gollob, J., Gandhi, P. J., Litchy, W. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001870 · Cited by 155 · see citing works

Forty years of experience with type I amyloid neuropathy. Review of 483 cases

Coutinho, P., da Silva, A. L., Lopes, J. M., Resende, P.-E. A., Silva, A. M. D., Resende, L. A. L., Silva, A. M.-D., Filho, J. D. L., & Barbosa, A. (1980) · Cited by 149 · see citing works

Cardiac transthyretin amyloidosis

Dungu, J. N., Anderson, L. J., Whelan, C. J., & Hawkins, P. N. (2012) · Heart · doi:10.1136/heartjnl-2012-301924 · Cited by 140 · see citing works

Antisense Strategies

Crooke, S. T. (2004) · Current Molecular Medicine · doi:10.2174/1566524043360375 · Cited by 140 · see citing works

Amyloid Neuropathies

Shin, S. C., & Robinson‐Papp, J. (2012) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.21352 · Cited by 138 · see citing works

Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy.

Gorevic, P. D., Prelli, F. C., Wright, J. R., Pras, M., & Frangione, B. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113966 · Cited by 133 · see citing works

One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition

Suhr, O. B., Lundgren, E., & Westermark, P. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12585 · Cited by 133 · see citing works

Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy

Lozeron, P., Théaudin, M., Mincheva, Z., Ducot, B., Lacroix, C., Adams, D., & French Network for FAP (CORNAMYL) (2013) · European Journal of Neurology · doi:10.1111/ene.12225 · Cited by 129 · see citing works

Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between late‐ and early‐onset cases in Portugal

Conceição, I. M., & de Carvalho, M. A. (2006) · Muscle & Nerve · doi:10.1002/mus.20644 · Cited by 128 · see citing works

Norfolk QOL‐DN : validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy

Vinik, E. J., Vinik, A. I., Paulson, J. F., Merkies, I. S. J., Packman, J., Grogan, D. R., & Coelho, T. (2014) · Journal of the Peripheral Nervous System · doi:10.1111/jns5.12059 · Cited by 114 · see citing works

THAOS: Gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease

Wixner, J., Mundayat, R., Karayal, O. N., Anan, I., Karling, P., Suhr, O. B., & on behalf of the THAOS investigators (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-61 · Cited by 112 · see citing works

Familial Amyloidosis: A Study of 52 North American-Born Patients Examined During a 30-Year Period

Gertz, M. A., Kyle, R. A., & Thibodeau, S. N. (1992) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60388-7 · Cited by 112 · see citing works

Plasminogen activation triggers transthyretin amyloidogenesis in vitro

Mangione, P. P., Verona, G., Corazza, A., Marcoux, J., Canetti, D., Giorgetti, S., Raimondi, S., Stoppini, M., Esposito, M., Relini, A., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003990 · Cited by 111 · see citing works

Hereditary ATTR amyloidosis: a single-institution experience with 266 patients

Swiecicki, P. L., Zhen, D. B., Mauermann, M. L., Kyle, R. A., Zeldenrust, S. R., Grogan, M. A., Dispenzieri, A. A., & Gertz, M. A. (2015) · Amyloid · doi:10.3109/13506129.2015.1019610 · Cited by 110 · see citing works

Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study

Planté‐Bordeneuve, V., Gorram, F., Salhi, H., Nordine, T., Ayache, S. S., Corvoisier, P. L., Azoulay, D., Féray, C., Damy, T., & Lefaucheur, J. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8337-3 · Cited by 108 · see citing works

Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis

Sekijima, Y., Yazaki, M., Oguchi, K., Ezawa, N., Yoshinaga, T., Yamada, M., Yahikozawa, H., Watanabe, M., Kametani, F., & Ikeda, S. (2016) · Neurology · doi:10.1212/wnl.0000000000003001 · Cited by 104 · see citing works

Recent advances in the treatment of familial amyloid polyneuropathy

Adams, D. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612470192 · Cited by 100 · see citing works

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area

Cortese, A., Vita, G., Luigetti, M., Russo, M., Bisogni, G., Sabatelli, M., Manganelli, F., Santoro, L., Cavallaro, T., Fabrizi, G. M., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8064-9 · Cited by 98 · see citing works

Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study

Matsuda, M., Gono, T., Morita, H., Katoh, N., Kodaira, M., & Ikeda, S. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03215.x · Cited by 97 · see citing works

The use of the New york heart association's classification of cardiovascular disease as part of the patient's complete problem list

Hurst, J. W., Morris, D. C., & Alexander, R. W. (1999) · Clinical Cardiology · doi:10.1002/clc.4960220604 · Cited by 96 · see citing works

[Cardiac Transthyretin Amyloidosis].

Manganiello, C. F. (2020) · PubMed · Cited by 96 · see citing works

Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin

Higaki, J. N., Chakrabartty, A., Galant, N. J., Hadley, K. C., Hammerson, B., Nijjar, T., Torres, R., Tapia, J. R., Salmans, J., Barbour, R., et al. (2016) · Amyloid · doi:10.3109/13506129.2016.1148025 · Cited by 88 · see citing works

Tafamidis

Saïd, G., Grippon, S., & Kirkpatrick, P. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3675 · Cited by 86 · see citing works

Systemic amyloidosis: a challenge for the rheumatologist

Perfetto, F., Pignone, A. M., Livi, R., Tempestini, A., Bergesio, F., & Matucci‐Cerinic, M. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.84 · Cited by 86 · see citing works

Survival After Transplantation in Patients With Mutations Other Than Val30Met

Suhr, O. B., Larsson, M., Ericzon, B., & Wilczek, H. (2015) · Transplantation · doi:10.1097/tp.0000000000001021 · Cited by 76 · see citing works

FAP Neuropathy and Emerging Treatments

Adams, D., Théaudin, M., Cauquil, C., Algalarrondo, V., & Slama, M. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0435-3 · Cited by 71 · see citing works

Impact of Liver Transplantation on Transthyretin-Related Ocular Amyloidosis in Japanese Patients

Hara, R. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.390 · Cited by 71 · see citing works

Marked Regression of Abdominal Fat Amyloid in Patients With Familial Amyloid Polyneuropathy During Long-Term Follow-Up After Liver Transplantation

Tsuchiya, A., Yazaki, M., Kametani, F., Takei, Y., & Ikeda, S. (2008) · Liver Transplantation · doi:10.1002/lt.21395 · Cited by 67 · see citing works

Aboard transthyretin: From transport to cleavage

Liz, M. A., Mar, F. M., Franquinho, F., & Sousa, M. M. (2010) · IUBMB Life · doi:10.1002/iub.340 · Cited by 66 · see citing works

Novel Drugs Targeting Transthyretin Amyloidosis

Hanna, M. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-013-0182-4 · Cited by 65 · see citing works

Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis

Damy, T., Judge, D. P., Kristen, A. V., Berthet, K., Li, H., & Aarts, J. M. (2015) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-015-9613-9 · Cited by 64 · see citing works

De novo malignancies following liver transplantation: a case–control study with long‐term follow‐up

Yao, F. Y., Gautam, M., Palese, C., Rebres, R., Terrault, N. A., Roberts, J. P., & Peters, M. G. (2006) · Clinical Transplantation · doi:10.1111/j.1399-0012.2006.00527.x · Cited by 60 · see citing works

Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study

Ando, Y., Sekijima, Y., Obayashi, K., Yamashita, T., Ueda, M., Misumi, Y., Morita, H., Machii, K., Ohta, M., Takata, A., et al. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.046 · Cited by 57 · see citing works

Pathogenesis of transthyretin amyloidosis

Benson, M. D. (2012) · Amyloid · doi:10.3109/13506129.2012.668501 · Cited by 40 · see citing works

Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses

Galant, N. J., Bugyei‐Twum, A., Rakhit, R., Walsh, P. J., Sharpe, S. J., Arslan, P. E., Westermark, P., Higaki, J. N., Torres, R., Tapia, J. R., et al. (2016) · Scientific Reports · doi:10.1038/srep25080 · Cited by 37 · see citing works

Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity

Singh, B. K., Haque, S. E., & Pillai, K. K. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.856881 · Cited by 34 · see citing works

Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease

Klimtchuk, E. S., Prokaeva, T. B., Frame, N. M., Abdullahi, H., Spencer, B., Dasari, S., Cui, H., Berk, J. L., Kurtin, P. J., Connors, L. H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802977115 · Cited by 34 · see citing works

New spastic paraplegia phenotype associated to mutation of NFU1

Tonduti, D., Dorboz, I., Imbard, A., Slama, A., Boutron, A., Pichard, S., Elmaleh, M., Vallée, L., Benoist, J., de Baulny, H. O., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0237-6 · Cited by 33 · see citing works

Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation

Drent, G., Graveland, C. W., Hazenberg, B. P. C., & Haagsma, E. B. (2009) · Amyloid · doi:10.1080/13506120903090726 · Cited by 29 · see citing works

Familial amyloidotic polyneuropathy: long-term follow-up of abdominal fat tissue aspirate in patients with and without liver transplantation

Haagsma, E. B., Gameren, I. I. V., Bijzet, J., Posthumus, M. D., & Hazenberg, B. P. C. (2007) · Amyloid · doi:10.1080/13506120701461368 · Cited by 24 · see citing works

Newer Therapies for Amyloid Cardiomyopathy

Chakraborty, R., Muchtar, E., & Gertz, M. A. (2016) · Current Heart Failure Reports · doi:10.1007/s11897-016-0300-1 · Cited by 16 · see citing works

Cardiovascular Risk of NSAIDs: Time to Translate Knowledge into Practice

Reddy, K. S., & Roy, A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001389 · Cited by 16 · see citing works

Phase 1 study of ALN-TTRsc02, a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis

Adams, D. H., & Karsten, V. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.01.339 · Cited by 15 · see citing works

Phase 2 Open-Label Extension (OLE) Study of Patisiran, an Investigational RNA interference (RNAi) Therapeutic for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (S27.004)

Adams, D., Coelho, T., Conceição, I. M., Waddington‐Cruz, M., Schmidt, H., Buades, J., Campistol, J. M., Pouget, J., Berk, J. L., Polydefkis, M. J., et al. (2017) · Neurology · doi:10.1212/wnl.88.16_supplement.s27.004 · Cited by 12 · see citing works

Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation (OLT)

Adams, D., Buades, J., Suhr, O. B., Obici, L. P., & Coelho, T. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-10-s1-p19 · Cited by 12 · see citing works

Analysis of disease progression in patients with transthyretin cardiac amyloidosis

Gilmore, J. D., Maurer, M. S., Vest, J., Karsten, V., Powell, C., Strahs, A. L., Gollob, J., & Hawkins, P. N. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-10-s1-o10 · Cited by 4 · see citing works

Phase 2 open-label extension study of patisiran, an investigational siRNA agent for hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN)

Conceição, I. M., Suhr, O. B., Coelho, T., Waddington‐Cruz, M., Schmidt, H., Buades, J., Campistol, J. M., Pouget, J., Berk, J. L., & Adams, D. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.06.206 · Cited by 3 · see citing works

Infusion related reactions in patients with hATTR amyloidosis treated with patisiran

Polydefkis, M. J., Adams, D., Coelho, T., Kristen, A. V., González‐Duarte, A., Berk, J. L., Quan, D., Partisano, A. M., Gollob, J., Sweester, M., et al. (2018) · Journal of the Peripheral Nervous System · Cited by 2 · see citing works

Efficiency of siRNA for removal of transthyretin V30M in a TTR leptomeningeal animal model

Gonçalves, P., Martins, S., Costelha, S., & Saraiva, M. J. (2017) · Amyloid · doi:10.1080/13506129.2016.1272452 · Cited by 2 · see citing works

Safety and Efficacy of Long-Term Diflunisal Administration in Familial Amyloid Polyneuropathy (PD1.009)

Sekijima, Y., Tojo, K., Morita, H., Koyama, J., Koike, H., Sobue, G., & Ikeda, S. (2013) · Neurology · doi:10.1212/wnl.80.7_supplement.pd1.009 · Cited by 1 · see citing works

The Potential for microRNA Therapeutics and Clinical Research

Hanna, J., Hossain, G. S., & Kocerha, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00478 · Cited by 729 · see citing works

Advances in COVID-19 mRNA vaccine development

Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works

Lipid Nanoparticles for Drug Delivery

Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100109 · Cited by 568 · see citing works

The Limitless Future of RNA Therapeutics

Damase, T. R., Sukhovershin, R. A., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 549 · see citing works

Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities

Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 544 · see citing works

The growth of siRNA-based therapeutics: updated clinical studies

Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497 · see citing works

Targeting non-coding RNAs to overcome cancer therapy resistance

Chen, B., Dragomir, M. P., Chen, Y., Li, Q., Horst, D. A., & Călin, G. A. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00975-3 · Cited by 442 · see citing works

RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs

Bajan, S., & Hutvágner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 399 · see citing works

Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver

Kim, M., Jeong, M., Hur, S., Cho, Y., Park, J., Jung, H. R., Seo, Y., Woo, H., Nam, K. T., Lee, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf4398 · Cited by 390 · see citing works

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

Traber, G. M., & Yu, A. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 301 · see citing works

Antibiotic failure: Beyond antimicrobial resistance

de la Fuente‐Núñez, C., Cesaro, A., & Hancock, R. E. W. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101012 · Cited by 263 · see citing works

Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates

Brown, K. M., Nair, J. K., Janas, M. M., Anglero-Rodriguez, Y. I., Dang, L. T. H., Peng, H., Theile, C. S., Castellanos-Rizaldos, E., Brown, C., Foster, D., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01334-x · Cited by 258 · see citing works

Histone Modifications and Non-Coding RNAs: Mutual Epigenetic Regulation and Role in Pathogenesis

Bure, I. V., Nemtsova, M. V., & Kuznetsova, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105801 · Cited by 258 · see citing works

Engineering siRNA therapeutics: challenges and strategies

Zaidi, S. S. A., Fatima, F., Zaidi, S. A. A., Zhou, D., Deng, W., & Liu, S. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02147-z · Cited by 266 · see citing works

Gene therapy clinical trials, where do we go? An overview

Arabi, F., Mansouri, V., & Ahmadbeigi, N. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113324 · Cited by 233 · see citing works

A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19

Idris, A., Davis, A. M., Supramaniam, A., Acharya, D., Kelly, G., Tayyar, Y., West, N. P., Zhang, P., McMillan, C. L. D., Soemardy, C., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.004 · Cited by 164 · see citing works

Approved Nanomedicine against Diseases

Jia, Y., Jiang, Y., He, Y., Zhang, W., Zou, J., Magar, K. T., Boucetta, H., Teng, C., & He, W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030774 · Cited by 169 · see citing works

Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy

Mukherjee, A., Bisht, B., Dutta, S., & Paul, M. K. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00902-w · Cited by 162 · see citing works

Recent Advances in Stimulus‐Responsive Nanocarriers for Gene Therapy

Cheng, Y., Li, L., Hu, P., Yang, Y., Wei, W., Deng, X., Wang, L., Tay, F. R., & Ma, J. (2021) · Advanced Science · doi:10.1002/advs.202100540 · Cited by 160 · see citing works

Where should siRNAs go: applicable organs for siRNA drugs

Ahn, I., Kang, C. S., & Han, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00998-y · Cited by 151 · see citing works

Editorial focus: understanding off-target effects as the key to successful RNAi therapy

Bartoszewski, R., & Sikorski, A. F. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0196-3 · Cited by 150 · see citing works

Therapeutic potential of RNA-enriched extracellular vesicles: The next generation in RNA delivery via biogenic nanoparticles

Muskan, M., Abeysinghe, P., Cecchin, R., Branscome, H., Morris, K. V., & Kashanchi, F. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.025 · Cited by 142 · see citing works

mRNA in the Context of Protein Replacement Therapy

Vavilis, T., Stamoula, Ε., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., & Vizirianakis, I. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010166 · Cited by 143 · see citing works

Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review

Ranasinghe, P., Addison, M. L., Dear, J. W., & Webb, D. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.15972 · Cited by 138 · see citing works

The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives

Walgrave, H., Zhou, L., Strooper, B. D., & Salta, E. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00496-7 · Cited by 132 · see citing works

Aptamers: Cutting edge of cancer therapies

Shigdar, S. L., Schrand, B., Giangrande, P. H., & de Franciscis, V. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.010 · Cited by 128 · see citing works

Current RNA-based Therapeutics in Clinical Trials

Zhou, L., Qin, Z., Zhu, Y., He, Z., & Xu, T. (2019) · Current Gene Therapy · doi:10.2174/1566523219666190719100526 · Cited by 114 · see citing works

The Role of Noncoding Variants in Heritable Disease

French, J. D., & Edwards, S. L. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.07.004 · Cited by 114 · see citing works

Recent advances in using liposomes for delivery of nucleic acid-based therapeutics

Nsairat, H., Alshaer, W., Odeh, F., Esawi, E., Khater, D., Bawab, A. A., El‐Tanani, M., Awidi, A., & Mubarak, M. S. (2023) · OpenNano · doi:10.1016/j.onano.2023.100132 · Cited by 107 · see citing works

Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery

Tai, W. (2019) · Molecules · doi:10.3390/molecules24122211 · Cited by 97 · see citing works

RNA therapeutics in the clinic

Curreri, A. M., Sankholkar, D., Mitragotri, S., & Zhao, Z. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10374 · Cited by 96 · see citing works

Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy

Zhang, C., Ma, Y., Zhang, J., Kuo, J. C., Zhang, Z., Xie, H., Zhu, J., & Liu, T. (2022) · Molecules · doi:10.3390/molecules27061943 · Cited by 93 · see citing works

ATTR Epidemiology, Genetics, and Prognostic Factors

Obi, C. A., Mostertz, W. C., Griffin, J. M., & Judge, D. P. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1066 · Cited by 90 · see citing works

TGFβ signaling pathways in human health and disease

Chen, P., Qin, L., & Simons, M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1113061 · Cited by 84 · see citing works

Role of miRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics

Roy, B., Lee, E. J., Li, T., & Rampersaud, M. (2022) · Genes · doi:10.3390/genes13030425 · Cited by 81 · see citing works

The Implications of ncRNAs in the Development of Human Diseases

López-Jiménez, E. A., & Andrés‐León, E. (2021) · Non-Coding RNA · doi:10.3390/ncrna7010017 · Cited by 80 · see citing works

Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury

Lee, T. J., Yuan, X., Kerr, K. M., Yoo, J. Y., Kim, D., Kaur, B., & Eltzschig, H. K. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.019026 · Cited by 78 · see citing works

Oligonucleotides to the (Gene) Rescue: FDA Approvals 2017–2019

Rüger, J., Ioannou, S., Castanotto, D., & Stein, C. A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.10.009 · Cited by 77 · see citing works

Microfluidic production and characterization of biofunctionalized giant unilamellar vesicles for targeted intracellular cargo delivery

Staufer, O., Antona, S., Zhang, D. J., Csatári, J., Schröter, M., Janiesch, J., Fabritz, S., Berger, I., Platzman, I., & Spatz, J. P. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120203 · Cited by 76 · see citing works

In vivo and in vitro studies of antisense oligonucleotides – a review

Kilanowska, A., & Studzińska, S. (2020) · RSC Advances · doi:10.1039/d0ra04978f · Cited by 76 · see citing works

Nucleic acid therapeutics: Past, present, and future

Naeem, S., Zhang, J., Zhang, Y., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102440 · Cited by 78 · see citing works

Cardiac amyloidosis‐A review of current literature for the practicing physician

Ash, S., Shorer, E. F., Ramgobin, D., Vo, M., Gibbons, J., Golamari, R. R., Jain, R., & Jain, R. (2021) · Clinical Cardiology · doi:10.1002/clc.23572 · Cited by 71 · see citing works

Nose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties

Kurano, T., Kanazawa, T., Ooba, A., Masuyama, Y., Maruhana, N., Yamada, M., Iioka, S., Ibaraki, H., Kosuge, Y., Kondo, H., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.017 · Cited by 73 · see citing works

Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids

Khalil, I. A., Younis, M. A., Kimura, S., & Harashima, H. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00743 · Cited by 67 · see citing works

Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development

Marques, R., Lacerda, R., & Romão, L. (2022) · Biomedicines · doi:10.3390/biomedicines10081865 · Cited by 65 · see citing works

Renal amyloidosis: an update on diagnosis and pathogenesis

Gupta, N., Kaur, H., & Wajid, S. (2020) · PROTOPLASMA · doi:10.1007/s00709-020-01513-0 · Cited by 62 · see citing works

Transdermal delivery of small interfering RNAs with topically applied mesoporous silica nanoparticles for facile skin cancer treatment

Lio, D. C. S., Liu, C., Oo, M. M. S., Wiraja, C., Teo, M. H. Y., Zheng, M., Chew, S. W. T., Wang, X., & Xu, C. (2019) · Nanoscale · doi:10.1039/c9nr06303j · Cited by 61 · see citing works

Progress on ocular siRNA gene‐silencing therapy and drug delivery systems

Jiang, J., Zhang, X., Tang, Y., Li, S., & Chen, J. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12561 · Cited by 56 · see citing works

The Power of Field-Flow Fractionation in Characterization of Nanoparticles in Drug Delivery

Bian, J., Gobalasingham, N. S., Purchel, A. A., & Lin, J. (2023) · Molecules · doi:10.3390/molecules28104169 · Cited by 54 · see citing works

Cationic nanocarriers: A potential approach for targeting negatively charged cancer cell

Vishwakarma, M., Agrawal, P., Soni, S., Tomar, S., Haider, T., Kashaw, S. K., & Soni, V. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103160 · Cited by 54 · see citing works

Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatment

He, Y., Zhang, W., Xiao, Q., Fan, L., Huang, D., Chen, W., & He, W. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.11.002 · Cited by 53 · see citing works

Applications of RNA interference in the treatment of arthritis

Rai, M. F., Pan, H., Yan, H., Sandell, L. J., Pham, C. T. N., & Wickline, S. A. (2019) · Translational research · doi:10.1016/j.trsl.2019.07.002 · Cited by 52 · see citing works

Small RNAs, spermatogenesis, and male infertility: a decade of retrospect

Joshi, M., Sethi, S., Mehta, P., Kumari, A., & Rajender, S. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01155-w · Cited by 51 · see citing works

The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides

Bege, M., & Borbás, A. (2022) · Pharmaceuticals · doi:10.3390/ph15080909 · Cited by 49 · see citing works

Nanoparticles and siRNA: a new era in therapeutics?

Pérez-Carrión, M. D., Posadas, I., & Ceña, V. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107102 · Cited by 48 · see citing works

The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development

Li, X., Bhullar, A. S., Binzel, D. W., & Guo, P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114316 · Cited by 47 · see citing works

Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran

Titze-de-Almeida, S. S., Brandão, P. R. D. P., Faber, I., & Titze‐de‐Almeida, R. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00434-w · Cited by 47 · see citing works

The Growing Class of Novel RNAi Therapeutics

Traber, G. M., & Yu, A. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000895 · Cited by 46 · see citing works

The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine

Forgham, H., Chang, Y.-X., Wang, Y., Zhu, J., Liu, L., Biggs, H., Käkinen, A., Jiang, Y., You, X., Thurecht, K. J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx1576 · Cited by 48 · see citing works

Human Clinical Relevance of the Porcine Model of Pseudoallergic Infusion Reactions

Szebeni, J., & Bawa, R. (2020) · Biomedicines · doi:10.3390/biomedicines8040082 · Cited by 45 · see citing works

Recent advances in understanding of the mechanisms of RNA interference in insects

Koo, J., & Palli, S. R. (2024) · Insect Molecular Biology · doi:10.1111/imb.12941 · Cited by 44 · see citing works

Chemical modulation of siRNA lipophilicity for efficient delivery

Tai, W. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.022 · Cited by 44 · see citing works

2024 Update on Classification, Etiology, and Typing of Renal Amyloidosis: A Review

Leung, N., & Nasr, S. H. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.01.530 · Cited by 43 · see citing works

Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics

Lee, Y., Jeong, M., Lee, G., Park, J., Jung, H., Im, S., & Lee, H. (2024) · Biomaterials Research · doi:10.34133/bmr.0017 · Cited by 46 · see citing works

Lipid‐Modified Aminoglycosides for mRNA Delivery to the Liver

Yu, X., Liu, S., Cheng, Q., Wei, T., Lee, S. M., Zhang, D., & Siegwart, D. J. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901487 · Cited by 44 · see citing works

miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma

Fuertes, T., Ramiro, A. R., & de Yébenes, V. G. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.08.006 · Cited by 42 · see citing works

Harnessing host–virus evolution in antiviral therapy and immunotherapy

Heaton, S. M. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1067 · Cited by 41 · see citing works

Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking

Mangla, P., Vicentini, Q., & Biscans, A. (2023) · Cells · doi:10.3390/cells12182253 · Cited by 40 · see citing works

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis

Gertz, M. A., Scheinberg, M., Waddington-Cruz, M., Heitner, S. B., Karam, C., Drachman, B., Khella, S., Whelan, C., & Obici, L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1635008 · Cited by 38 · see citing works

Mitochondrion-targeted RNA therapies as a potential treatment strategy for mitochondrial diseases

Chernega, T., Choi, J., Salmena, L., & Andreazza, A. C. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.10.012 · Cited by 38 · see citing works

Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines

Valcourt, D. M., Kapadia, C. H., Scully, M. A., Dang, M. N., & Day, E. S. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000110 · Cited by 38 · see citing works

Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs

Baylot, V., Le, T. K., Taïeb, D., Rocchi, P., & Colleaux, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06121-9 · Cited by 41 · see citing works

Transthyretin Stabilization: An Emerging Strategy for the Treatment of Alzheimer’s Disease?

Saponaro, F., Kim, J. H., & Chiellini, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228672 · Cited by 36 · see citing works

Engineered Lipid Nanoparticles for the Treatment of Pulmonary Fibrosis by Regulating Epithelial‐Mesenchymal Transition in the Lungs

Jin, H. K., Jeong, M., Lee, G., Kim, M., Yoo, Y., Kim, H. J., Cho, J., Lee, Y., & Lee, H. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202209432 · Cited by 36 · see citing works

Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases

Park, G. Y., Jamerlan, A., Shim, K. H., & An, S. S. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122982 · Cited by 35 · see citing works

Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery

Eygeris, Y., Henderson, M. I., Curtis, A. G., Jozić, A., Stoddard, J., Reynaga, R., Chirco, K. R., Su, G., Neuringer, M., Lauer, A. K., et al. (2024) · Small · doi:10.1002/smll.202400815 · Cited by 34 · see citing works

Pulmonary Aerosol Delivery of Let‐7b microRNA Confers a Striking Inhibitory Effect on Lung Carcinogenesis through Targeting the Tumor Immune Microenvironment

Zhang, Q., Pan, J., Xiong, D., Wang, Y., Miller, M. S., Sei, S., Shoemaker, R. H., Izzotti, A., & You, M. (2021) · Advanced Science · doi:10.1002/advs.202100629 · Cited by 33 · see citing works

Preventing occludin tight-junction disruption via inhibition of microRNA-193b-5p attenuates viral load and influenza-induced lung injury

Vaswani, C. M., Varkouhi, A. K., Gupta, S., Ektesabi, A. M., Tsoporis, J. N., Yousef, S., Plant, P. J., da Silva, A. L., Cen, Y., Tseng, Y., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.011 · Cited by 34 · see citing works

Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics

Zeng, L., Li, D., Tong, W., Shi, T., & Ning, B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114424 · Cited by 32 · see citing works

Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging

Alradwan, I. A., Fayez, N. A., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., Alsulami, K. A., Aldossary, A. M., Alawad, A. O., Tawfik, Y. M. K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081037 · Cited by 37 · see citing works

Advances in nucleic acid-targeted therapies for cardiovascular disease prevention

Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 30 · see citing works

Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies

Padmakumar, S., D’souza, A. A., Parayath, N. N., Bleier, B. S., & Amiji, M. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.018 · Cited by 30 · see citing works

MicroRNA Networks in Cognition and Dementia

Blount, G. S., Coursey, L., & Kocerha, J. (2022) · Cells · doi:10.3390/cells11121882 · Cited by 29 · see citing works

Biosafety assessment of delivery systems for clinical nucleic acid therapeutics

Li, Z., Zhang, L., Jiang, K., Zhang, Y., Liu, Y., Hu, G., & Song, J. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2022.03.003 · Cited by 28 · see citing works

A review on Gaucher disease: therapeutic potential of β-glucocerebrosidase-targeted mRNA/saRNA approach

Feng, S., Rcheulishvili, N., Jiang, X., Zhu, P., Pan, X., Wei, M., Wang, P. G., Ji, Y., & Papukashvili, D. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.87741 · Cited by 27 · see citing works

Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review

To, N. H., Nguyen, H. Q., Thiolat, A., Liu, B., Cohen, J. L., Radosevic‐Robin, N., & Belkacémi, Y. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06533-3 · Cited by 26 · see citing works

Insight into the siRNA transmembrane delivery—From cholesterol conjugating to tagging

Zheng, Y., & Tai, W. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1606 · Cited by 27 · see citing works

Nanotechnology-Enhanced siRNA Delivery: Revolutionizing Cancer Therapy

Esmaeilpour, D., Ghomi, M., Zare‬, E. N., & Sillanpää, M. E. T. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00489 · Cited by 30 · see citing works

RNAi therapeutic strategies for acute respiratory distress syndrome

Jagrosse, M. L., Dean, D. A., Rahman, A., & Nilsson, B. L. (2019) · Translational research · doi:10.1016/j.trsl.2019.07.011 · Cited by 25 · see citing works

RNAi-Based Approaches for Pancreatic Cancer Therapy

Kim, M. J., Chang, H., Nam, G., Ko, Y., Kim, S. H., Roberts, T. M., & Ryu, J. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101638 · Cited by 25 · see citing works

Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis

Dohrn, M. F., Medina, J., Dague, K. O., & Hund, E. (2021) · Neurological Research and Practice · doi:10.1186/s42466-021-00155-8 · Cited by 26 · see citing works

MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection—Narrative Review

Poniewierska-Baran, A., Zadroga, Ł., Danilyan, E., Małkowska, P., Niedźwiedzka‐Rystwej, P., & Pawlik, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065386 · Cited by 25 · see citing works

α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice

Rodríguez-Castejón, J., Alarcia-Lacalle, A., Gómez-Aguado, I., Vicente-Pascual, M., Solinís, M. Á., del Pozo‐Rodríguez, A., & Rodríguez‐Gascón, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060771 · Cited by 24 · see citing works

Role of epigallocatechin-3- gallate in the regulation of known and novel microRNAs in breast carcinoma cells

Banerjee, S., & Mandal, A. K. A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.995046 · Cited by 24 · see citing works

ELAC2, an Enzyme for tRNA Maturation, Plays a Role in the Cleavage of a Mature tRNA to Produce a tRNA-Derived RNA Fragment During Respiratory Syncytial Virus Infection

Choi, E.-J., Wu, W., Zhang, K., Lee, I., Kim, I.-H., Lee, Y. S., & Bao, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.609732 · Cited by 23 · see citing works

Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis

Alsaadi, M., Khan, M. Y., Dalhat, M. H., Bahashwan, S., Khan, M. U., Albar, A. H., Almehdar, H. A., & Qadri, I. (2021) · Diagnostics · doi:10.3390/diagnostics11101739 · Cited by 23 · see citing works

Molecular Therapies in Cardiovascular Diseases: Small Interfering RNA in Atherosclerosis, Heart Failure, and Hypertension

Sarzani, R., Spannella, F., Pentima, C. D., Giulietti, F., Landolfo, M., & Allevi, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010328 · Cited by 23 · see citing works

Microfluidics for Nanomedicine Delivery

Chen, K., Yang, H., & Cai, R. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02052 · Cited by 22 · see citing works

Small RNAs: An expanding world with therapeutic promises

Gou, L., Zhu, Q., & Liu, M. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.03.003 · Cited by 21 · see citing works

GL67 lipid-based liposomal formulation for efficient siRNA delivery into human lung cancer cells

Jarallah, S. J., Aldossary, A. M., Tawfik, E. A., Altamimi, R. M., Alsharif, W. K., Alzahrani, N. M., Sobeai, H. M. A., Qamar, W., Alfahad, A. J., Alshabibi, M. A., et al. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.05.017 · Cited by 22 · see citing works

Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis

Yang, J. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567326 · Cited by 71 · see citing works

An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis

Milani, P., Mussinelli, R., Perlini, S., Palladini, G. O., & Obici, L. P. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1671352 · Cited by 11 · see citing works

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

Adams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A. V., Schmidt, H. H., Berk, J. L., Losada López, I. A., Dispenzieri, A., Quan, D., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30368-9 · Cited by 158 · see citing works

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047 · see citing works

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis

Urits, I., Swanson, D., Swett, M. C., Patel, A., Berardino, K., Amgalan, A., Berger, A. A., Kassem, H., Kaye, A. D., & Viswanath, O. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00208-1 · Cited by 268 · see citing works